German Tech Holding GmbH & Co. KGaA: Investment opportunity in Zirnostics

Frankfurt am Main (pta024/22.10.2026/19:03 UTC+2)

• Supplementary information and background on the investment opportunity in Zirnostics GmbH
• Description of Zirnostics by First Berlin Equity Research

Frankfurt/Main, 22 October 2026 – German Tech Holding (GTH) reports on supplementary aspects of and background to the investment opportunity in Zirnostics GmbH presented on 7 October 2026.

The market addressed by Zirnostics with its PSMA PET/CT tracer is currently defined by two short-lived isotopes: gallium-68, with a half-life of approximately 68 minutes, and fluorine-18, with a half-life of approximately 110 minutes. The short half-life of these isotopes represents a significant limitation, as it restricts the window for imaging to approximately one hour after administration. Nevertheless, all currently approved preparations are based on these two isotopes and together generated revenues of just under 2 billion US dollars in 2025.

The limiting factor is therefore not targeting, but time. Because imaging with gallium-68- and fluorine-18-based PSMA PET/CT tracers must take place shortly after injection, a tracer (radiolabelled substance for medical imaging) that has not bound to tumor tissue has only very limited opportunity to be cleared from the blood and surrounding tissue. With legacy tracers, the detection of small recurrent foci and metastases, which can be decisive for further therapy planning and its success, is particularly challenging. Extending the interval between administration of the tracer and imaging addresses this problem and considerably improves detection. In the zirconium-89 studies, mean tracer uptake in suspicious lesions rose from 5.1 at one hour to 11.6 at 24 hours and 13.5 at 48 hours, with tumor-to-background contrast increasing significantly between the time points. In a study with 23 patients, only one of 36 lesions was visible on the PSMA PET/CT scan after one hour. The clinical potential of long-lived PSMA tracers is already supported by further studies. For example, a prospective study with a copper-64-based tracer showed a considerably higher positivity rate than a conventional gallium-68 preparation (78 % versus 36 %).

This copper-64-based tracer was developed by Clarity Pharmaceuticals, a challenger to the legacy providers that has been listed in Australia since 2021. Copper-64-SAR-bisPSMA uses a half-life of 12.7 hours to enable next-day imaging. The programme is in Phase III of several registrational trials, i.e. still prior to marketing authorization by the authorities. Clarity's market capitalization naturally reflects its advanced stage of development.

Zirnostics likewise harnesses the potential of long-lived PSMA tracers to further improve prostate cancer diagnostics. With a half-life of 78.4 hours, zirconium-89 permits imaging even after three to seven days and thus offers a considerably longer imaging window than copper-64 with a half-life of only 12.7 hours. The published clinical data are consistent with the mechanism: positivity rates of 72–79 % in patients whose conventional PSMA PET/CT was negative or inconclusive, including 72.3 % at a tumor marker (prostate-specific antigen, PSA) level of ≤ 0.2 ng/ml – a setting in which conventional imaging struggles to localize recurrent disease. Among the patients subsequently treated with imaging-guided radiotherapy in the 2026 study, 80 % achieved a PSA reduction of at least 50 %.

With the use of the zirconium-89-labelled tracer developed by Zirnostics compared with conventional tracers, the tumor contrast in imaging required for the detectability of tumor cells increases by a factor of up to 100.

In addition, a description of Zirnostics GmbH prepared by First Berlin Equity Research is now available on the website of German Tech Holding at the following link

https://germantechholding.com/wp-content/uploads/2026/10/Zirnostics-Description-2026-10-22-FB.pdf

About German Tech Holding

German Tech Holding (GTH) is an investment company founded in 2012 and based in Frankfurt am Main.

During its active years as a leading German venture capital provider under the name German Startups Group, GTH held stakes with great success in, among others, Chrono24, Delivery Hero, Fiagon, Mister Spex, Remerge and Scalable Capital. To this day it holds investments including AuctionTech, SoundCloud and Thinksurance. Through its SaaS-based white-label solution PropNow for digital bidding and offer processes in the real estate market, AuctionTech is the European market leader.

GTH pursues opportunities in the fields of artificial intelligence and life sciences/biotech. Cognicare AI, a spin-off from GTH's investment in the company builder Softmax AI, addresses the structurally growing market for senior care facilities with highly sought-after AI applications. In the field of life science, GTH is examining an investment opportunity in Zirnostics GmbH that has presented itself and has signed a term sheet in this regard. Zirnostics is preparing a clinical trial for the approval of its disruptive tracer for PSMA-PET/CT imaging in prostate cancer, which is up to 100-fold superior to legacy tracers in terms of tumor-to-background contrast and has already been successfully clinically tested for years in several hundred patients.

Securities ID number A1MMEV

ISIN DE000A1MMEV4

Symbol GTH

Further information: germantechholding.com

Investor Relations Contact

Rosenberg Strategic Communications
Mario Groß

MC Services AG

Fotini Vogiatzi

Important notice

The information document pursuant to Annex IX of Regulation (EU) 2017/1129 and the share purchase application are exclusively authoritative for the currently ongoing public offer. This press release constitutes neither investment advice nor an investment recommendation.

This press release contains forward-looking statements based on current assessments of the management. Such statements are subject to risks and uncertainties, in particular with regard to the completion of the investment transaction, the course of clinical trials, the granting of FDA and EMA approvals under pharmaceutical law and market developments. Actual developments may therefore differ materially. This announcement constitutes neither an offer to purchase or subscribe for securities nor investment advice or an investment recommendation.

Disclaimer

This publication is advertising. It constitutes neither an offer to sell nor a solicitation to purchase or subscribe for securities in any jurisdiction, in particular not in the United States of America. An investment decision may be made exclusively on the basis of the information document prepared by the issuer pursuant to Article 1 (4) subpara. 1 lit. db) of the Prospectus Regulation and in accordance with the requirements set out in Annex IX of the Prospectus Regulation, which is published at http://www.germantechholding.com under the heading "For Shareholders" (https://germantechholding.com/index.php/for-shareholders/the-share/) and has been filed with the Federal Financial Supervisory Authority ("BaFin"). BaFin, as the competent national authority, has neither reviewed nor approved this document. Potential investors should read the information document before making an investment decision in order to fully understand the potential risks and opportunities of the decision to invest in the securities.

This publication is not intended, either directly or indirectly, for distribution or dissemination into or within the United States of America (including its territories and possessions, any state of the United States or the District of Columbia) or to publications with a general circulation in the United States of America. The securities are not and will not be registered under the provisions of the U.S. Securities Act of 1933, as amended (the "Securities Act"), and may be sold or offered for purchase in the United States of America only with prior registration under the provisions of the Securities Act as currently in force or, without prior registration, only on the basis of an exemption. The issuer does not intend to register the offer of securities in whole or in part in the United States of America or to conduct a public offering in the United States of America.

Outside Germany, this publication is directed only at, and is intended exclusively for, those persons in member states of the EEA who are "qualified investors" within the meaning of Article 2(e) of the Prospectus Regulation ("qualified investors"). In addition, in the United Kingdom this publication is distributed only to, and is directed only at, those qualified investors (i) who have professional experience in matters relating to investments within the meaning of Article 19 (5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order"), (ii) who are high net worth companies within the meaning of Article 49(2)(a) to (d) of the Order, or (iii) who are other persons to whom this publication may lawfully be communicated.

This publication is not an offer to purchase securities in Canada, Japan or Australia.

(end)

Emitter:	German Tech Holding GmbH & Co. KGaA Humboldtstraße 60B 60318 Frankfurt am Main Germany
Contact Person:	Investor Relations
Phone:	+49 69 348690520
E-Mail:	ir@germantechholding.com
Website:	germantechholding.com
ISIN(s):	DE000A1MMEV4 (Share)
Stock Exchange(s):	Free Market in Dusseldorf, Frankfurt (Scale), Munich, Stuttgart, Tradegate BSX